Relatório de estágio curricular na Blueclinical Lda. by Órfão, Ema Sofia Lisboa
  
 
Universidade de Aveiro 
2013  
 Secção Autónoma de Ciências da Saúde  
Ema Sofia  
Lisboa Órfão 
 
Relatório de Estágio Curricular na Blueclinical Lda. 
 
Curricular Training Report in Blueclinical Ltd. 
 
 
 
   
  
  
 
Universidade de Aveiro 
2013 
Secção Autónoma de Ciências da Saúde 
Ema Sofia  
Lisboa Órfão 
 
 
Relatório de Estágio Curricular na Blueclinical Lda. 
 
Curricular Training Report in Blueclinical Ltd. 
 
 Tese apresentada à Universidade de Aveiro para cumprimento dos 
requisitos necessários à obtenção do grau de Mestre em Biomedicina 
Farmacêutica, realizada sob a orientação científica da professora 
Doutora Alexandra Queirós, Professora Coordenadora da Escola 
Superior de Saúde da Universidade de Aveiro e da Doutora Cristina 
Lopes, Diretora de Operações Clínicas da Blueclinical Lda. 
 
   
  
  
  
  
 
 
 
 Dedico este relatório aos meus pais. 
 
 
 
 
 
  
  
  
 
 
 
 
 
 
o júri   
 
Presidente Professor Doutor Bruno Miguel Alves Fernandes do Gago 
professor auxiliar convidado da Universidade de Aveiro 
 
  
Arguente 
 
 
 
Orientadora 
 
 
 
Orientadora 
Professora Doutora Maria Joana da Costa Gomes da Silva 
professora adjunta da Universidade de Aveiro 
 
Doutora Cristina Manuela Pinto Vieira Lopes 
diretora de operações clínicas e desenvolvimento de negócio da Blueclinical 
Lda. 
 
Professora Doutora Alexandra Isabel Cardador de Queirós 
professora coordenadora sem agregação da Universidade de Aveiro 
 
 
 
  
  
  
  
  
  
  
  
  
  
 
 
 
  
  
  
  
 
agradecimentos 
 
À Universidade de Aveiro, em especial ao Prof. Doutor Luís Almeida e ao Prof. 
Doutor Bruno Gago pela excelente direção do Mestrado. 
À Prof. Doutora Alexandra Queirós e à Doutora Cristina Lopes pela mestria 
com que me orientaram na elaboração deste relatório. 
Ao Prof. Doutor Luís Almeida, mais uma vez, e ao Prof. Doutor Sérgio Simões 
pela oportunidade. 
A toda a equipa da Blueclinical, em especial à Dra. Benedita Pereira por toda a 
simpatia, disponibilidade e ensinamentos ao longo dos últimos meses. 
Ao João Lemos pela amizade, paciência, apoio e porque estes 9 meses não 
tinham sido a mesma coisa sem ele. 
Ao Tiago Campos, por tudo o que ensinou durante o GIC04. 
À Alexandra Bernardino, à Márcia Correia e à Nádia Fernandes por terem 
tornado melhores estes cinco anos. 
Aos meus amigos Carolina, Joana e Tiago por me ouvirem e estarem sempre 
presentes para mim desde que me lembro. 
Ao Carlos Miguel por tudo. 
Aos meus pais, por serem os melhores do Mundo. 
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
  
palavras-chave 
 
Estudo clínico, dispositivos médicos, unidade de fase I, site management 
organisation, clinical study coordinator. 
 
resumo 
 
 
O presente relatório descreve com detalhe o meu período de estágio curricular 
como gestora de projeto. O estágio teve a duração de 9 meses e ocorreu na 
Blueclinical Lda, uma empresa constituída por três unidades de negócio 
distintas: uma unidade de fase I, serviços de gestão e coordenação de centros 
de ensaios e serviços de consultoria farmacêutica.  
 
A principal atividade desenvolvida foi a gestão de um estudo clínico com um 
dispositivo médico implantável ativo. Durante o período de estágio pude também 
desenvolver outras tarefas ao longo dos diferentes setores e compreender o seu 
funcionamento.  
Para além da descrição das atividades desenvolvidas é feita uma apresentação 
das principais dificuldades sentidas, das estratégias utilizadas para as 
ultrapassar e dos objetivos que acredito ter alcançado. 
 
Este estágio constitui o meu primeiro contacto com o mundo do trabalho, tendo-
me permitido aplicar e aprofundar os conhecimentos e competências adquiridos 
ao longo do meu percurso académico, concretamente durante o primeiro ano do 
Mestrado em Biomedicina Farmacêutica. 
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abstract 
 
The present report describes in detail the period of my curricular training as a  
project manager. The training lasted 9 months and occurred in Blueclinical Ltd, 
a company composed of three distinct business units: a phase I unit, site 
management organisation’s services and pharmaceutical consulting services. 
 
The main activity developed was the management of a clinical study of an active 
implanted medical device. During the training period I could also perform other 
tasks over the different sectors and understand its operation. 
Along with the description of the activites perform, it is done a presentation of the 
main difficulties encountered, the strategies used to overcome them and the 
goals that I believe I have achieved. 
 
This training constituted my first contact with the world of work, and allowed me 
to put into practice and deepen the knowledge and skills acquired throughout my 
academic course, particularly during the first year of the Master in 
Pharmaceutical Biomedicine. 
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1. INTRODUCTION 
The present report describes my training experience at Blueclinical Ltd, which constitutes part 
of my Master’s degree in Pharmaceutical Biomedicine. The internship lasted 9 months and started 
on 1st September, 2012. 
At the beginning of my training, and taking in to account the characteristics of the host 
company, I defined a set of primary objectives: 
 Develop a deep understanding about the regulatory framework of clinical trials and clinical 
studies;  
 Perform regulatory submission to the different national entities in the context of clinical 
investigation studies; 
 Develop and contact with different project management tools and techniques; 
 Understand the functioning of a phase I unit; 
 Understand basic concepts regarding the function and construction of a quality management 
system (QMS);  
 Contact with the reality of a national research site; 
I have also established a set of secondary objectives: 
 To develop interpersonal and soft skills, i.e. communication (oral and written), self-confidence, 
critical thinking, organisation, problem solving, responsibility sense and autonomy; 
 Establish a working contact network; 
 Identify potential areas of interest within the pharmaceutical industry. 
Regarding the report’s structure and contents, this work is organised in five chapters. The first 
chapter includes, apart from the defined training objectives, an overview of Blueclinical’s structure, 
mission and services. Chapter 2 gives respect to the state-of-the-art and here I present a brief 
description regarding the R&D model for medical devices (MD) and pharmaceuticals, highlighting 
some of their differences, as well as the applicable European regulatory framework concerning the 
clinical investigation process and the national situation. Chapter 3 entails a description of the 
activities developed and the different training sessions and meetings attendend. Chapter 4 
corresponds to the discussion, where I describe in general terms the main difficulties felt and the 
learning outcomes achieved. The last chapter corresponds to the conclusion. 
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1.1. HOST COMPANY OVERVIEW 
Blueclinical – Investigação e Desenvolvimento em Saúde, Ltd. is a company that was created 
in May 2012 and whose headquarters are located at Hospital da Prelada, level 3 – Ala Poente, Rua 
de Sarmento de Beires, 153, 4250-449 Porto. 
According to the type of services provided, Blueclinical is formed by three business units: 
Blueclinical SMO, Blueclinical Phase I and Blueclinical R&D (figure 1). These three business units 
allow Blueclinical to provide a complete range of services and competencies that cover all the 
different phases of the drug discovery process – from bench to bedside. 
 
 Figure 1 – Blueclinical’s general structure. 
 
 
 
 
 
SMO states for ‘site management organisation’, and in general terms it consists in 
organisations specialised in managing clinical research sites. Therefore, Blueclinical SMO intends 
ACSC: Associate clinical study coordinator; ALT: Associate laboratory technician; APM: Associate project manager;  
CD: Clinical director; COD: Clinical operations director; CRM: Clinical research manager; CSC: Clinical study coordinator; 
CTA: Clinical trial assistant; External support: Human resources, accountability, purchasing, finances; Internal support: 
Medical writing, statistics, pharmacokinetics, pharmacovigilance; LTc: Laboratory technician coordinator; MP: Managing 
partner; NC: Nurse coordinator; Nurs: Research nurses; Pharm: Research Pharmacist; Physi - Research physicians; PI: 
Principal investigator; PM: Project manager; QAM: Quality Management; R&D: Research and development; SMO: Site 
management organization. 
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to operate by establishing partnerships with target national hospitals, enhancing their ability to carry 
out research of excellence through its operational management; this is accomplished by integrating 
clinical study coordinator (CSC) onto the clinical research sites (1).  
The ultimate goal is to develop a network of highly effective clinical research sites. 
Blueclinical Phase I consists in a Human Pharmacology Unit located in Hospital da Prelada, 
Porto. Blueclinical has also established a protocol with Hospital CUF Descobertas, Porto. 
Blueclinical Phase I mission is the conduction of Phase I clinical trials, in healthy volunteers 
(at Hospital da Prelada) and in selected populations of patients (at Hospital CUF Descobertas). Its 
creation was based on the purpose of generating new opportunities at the clinical research level, 
mainly in the early stages of the clinical development, and as a way of supporting other companies 
in the development of their programs (2).  
The clinical team is composed by the clinical director, a group of medical investigators and 
their coordinator - the principal investigator (PI), and also a team of nurses and their coordinator. 
The phase I team also includes laboratory technicians, one pharmacist and the clinical research 
manager. 
Blueclinical R&D is focused on providing consulting services in pharmaceutical, non-clinical, 
clinical, regulatory and commercial development. The target client goes from national and 
international start-ups to universities and other public or private institutions. Blueclinical R&D 
services include: 
 Development of the global R&D plan of new drugs, MDs, and other health products; 
 Preparation and monitoring of the scientific and regulatory advice processes for regulatory 
authorities; 
 Planning and supervision of pharmaceutical development and analytical methods; 
 Defining and monitoring of the implementation of the nonclinical development plan;  
 Preparation of the investigator's brochure and investigational medicinal product (IMP) dossier; 
 Definition and monitoring of the clinical development plan; 
 Ethics and regulatory approval of clinical studies/trials; 
 Support in portfolio selection; 
 Business plan analysis; 
 Development of business plans and applications for obtaining financial support (3). 
Blueclinical R&D has also a group of external consultants experts in their area of action,that 
collaborate with the company. 
4 
 
 
5 
 
2. STATE-OF-THE-ART 
The pharmaceutical and the MD industries constitute two major players in human health (4). 
Pharmaceuticals are molecular-based compounds whose effectiveness depends on its 
interaction with the subject’s physiologic system (5). MD are generally engineer-based products with 
localised effects and whose good performance is dependent on their correct use. Given this obvious 
divergences, the two development models are also significantly different and, consequently, subject 
to different regulatory frameworks (4).  
 
2.1. R&D MODEL FOR PHARMACEUTICAL PRODUCTS  
The drug discovery process begins with developing a deep understanding of the disease and 
their causes.  After this, scientists start looking for a “target”, i.e. a gene or a protein, and try to 
demonstrate that it has a role in the disease’s physiopathology.  This “target validation” is done 
through the conduction of a series of experiments in living cells and animal models of disease. The 
next step is to find/develop a series of molecules/ “lead compounds” capable to interact with the 
selected target and cause the desired effect (6).  
These molecules are then subject to a series of tests (e.g. pharmacokinetic (PK) and toxicology 
tests) whose results will determine which compounds present the necessary characteristics to 
continue. After this initial screening, the remaining molecules’ structures are optimised in order to 
improve their properties (6).  
Before entering in clinical development, the compounds that arrived to this stage are tested in 
vitro and in vivo (animal studies) – the non-clinical development. The information obtained is  used 
to estimate a safe starting dose and doses range for clinical trials (7). 
In order to bring the new drug to the market a sponsor has to prove its efficacy, safety and 
quality through a series of clinical trials.    
Traditionally, clinical trials have been divided in four phases: 
 Phase I - studies designed to estimate tolerability and characterise the PK and pharmacologic 
profile of the IMP (7); 
 Phase II – studies whose primary objective is to explore the therapeutic efficiency of the drug 
candidate in patients; generally this is sub-divided in: phase IIa trials, that often use dose 
escalation designs for estimating the dose response, and phase IIb trials, that evaluate the efficacy 
of the drug candidate at the prescribed dose regimen (8, 9); 
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 Phase III – studies design to confirm that the drug is effective for use in the intended indication 
and population. The data generated will support the “prescribing information”; 
 Phase IV – studies conducted while the drug is already on the market (8); 
Data shows that nowadays the clinical development process has an average duration of nine 
years and constitute 58,6% of the product development costs. Also, the traditional and sequential 
model for drug development has been accused of being slow, expensive and shortly predictive of the 
true clinical effectiveness of the study drug (10). Several cases of big failures during the late stages 
of the clinical development process have led to the creation of a new development model: the “quick-
win, fast fail” paradigm  (figure 2) (11).  
 
Figure 2 – The traditional paradigm vs. the “quick win, fast fail” paradigm. Available from: Paul, Steven M. , 2010 
(11). 
 
 
This new approach intends to reduce technical uncertainty in the early stages (phase I/IIa) 
through the use of new tools and strategies. A good example is the conduction of proof-of-concept 
trials that will have the capacity of providing evidence that the molecular target is being hit and 
causing the desired physiological response (11, 12).This will result in a small number of new 
molecular entities entering in phase II/III but those that advance have a much higher probability of 
success. The savings gained from preventing costly failures can then be re-invested to further 
enhance R&D productivity (11). 
The process of granting a marketing authorisation for a certain medicine is based on 
risk/benefit analysis of the data produced during development. The assessment is done by the 
CS: Candidate selection; 
FED: First efficacy dose; 
FHD: First human dose;  
PD: Product decision;  
POC: Proof of concept; 
p(TS): Probability of success.  
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European Medicine Agency – centralised procedure, or by the different national competent 
authorities of the countries in cause - national, mutual recognition or decentralised procedures (13). 
 
2.1.1. CLINICAL TRIALS – REGULATORY FRAMEWORK 
Clinical research is an extremely regulated sector, with a series of laws and ethical standards 
in place. Their main purposes are to protect the rights and integrity of patients and study volunteers 
and to guarantee a high quality of the data produced/collected. 
The requirements for the conduction of clinical trials in Europe are established in the following 
documents: 
 Declaration of Helsinki; 
 International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP); 
 Directive 2001/20/EC, April 4th, on the approximation of the laws, regulations and administrative 
provisions of the Member States (MS) relating to the implementation of GCP in the conduct of 
clinical trials on medicinal products for human use; 
 Directive 2003/94/EC, October 8th, laying down the principles and guidelines of good 
manufacturing practice in respect of medicinal products for human use and IMPs for human use; 
 Directive 2005/28/EC, April 08th, laying down principles and detailed guidelines for GCP as 
regards IMP for human use, as well as the requirements for authorisation of the manufacturing 
or importation of such products; 
 Directive 95/46/EC, October 24th, on the protection of individuals with regard to the processing 
of personal data and on the free movement of such data (14). 
The clinical trials’ directive 2001/20/EC has been in place since May 2004 and represents the 
first attempt of the MS to harmonise the clinical trial approval process. 
 According to this directive, the conduction of a clinical trial is subject to a prior approval from 
two entities: the national competent authority and the central ethics committee of the country in 
question(15). In the context of a multicountry trial this results in multiple submission of the same 
documents to the different entities cross-country (15). 
Despite some improvements, the clinical trial directive 2001/20/EC did not provide the 
required level of harmonisation and it corresponds to the most criticised part of all the European 
medicines legislation (15, 16).  
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In fact, data showed that the directive had led to a significant delay in the approval of clinical 
trials, an increase in the costs involved and in a 25% reduction on the number of clinical trial 
applications (CTA) between 2007 and 2011 (16).   
As a consequence the European Commission has classified the need for new legislation as a 
priority in order to re-establish Europe’s competitiveness in terms of clinical research and on 17 July 
2012 a legal proposal for Clinical Trial Regulation has been adopted (16).   
The proposal intends to facilitate the conduction of multicenter trials by creating a new and 
simplified authorisation procedure. In short terms, this procedure will involve the construction of a 
submission dossier with two different parts: the “general part”, which will contain scientific 
information identical for all the MS, and the “national part”, that will include ethical and local 
information (e.g. compensation arrangements, insurance, and informed consent forms).  The dossier 
submission will be done through a portal – the “EU portal” (15, 16). The sponsor will be responsible 
for selecting a MS that will act as the “reporting MS” and will evaluate the “general part” of the 
submission dossier and prepare a report. The “national part” is evaluated by each MS. The two 
evaluations are followed by a pre-defined period during which questions can be raised (15).  
As this proposal will assume the form of a regulation (instead of a directive) the harmonisation 
of the rules governing the conduction of clinical trials in Europe will be safeguarded from different 
transpositions by the several MS (15).  
In terms of scope, the proposal covers all the interventional clinical trials of medicines for 
human use. Trials that involve no intervention are excluded. Moreover, it establishes that the so 
called “low-intervention clinical trials” (e.g. trials where the study drug is marketed and used in 
accordance with the terms of its marketing authorisation) should be subject to shorter timelines for 
approval (16). 
Projections state the regulation is expected to be effective in 2016, followed by a 3-year period 
during which both the directive 2001/20/EC and the regulation will be in place (15). 
 
2.1.2. CLINICAL TRIALS IN PORTUGAL  
The national framework for clinical trials is mainly governed by laws transposed from 
European Directives, namely Law nr. 46/2004, August 19th, which is the transposition of European 
Directive 2001/20/EC. According to it, the sponsor has to get approval / favourable opinion from the 
following entities: 
 National regulatory agency – Instituto Nacional da Farmácia e do Medicamento (INFARMED); 
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 National central ethics committee – Comissão de Ética para a Investigação Clínica (CEIC);  
 National data protection committee – Comissão Nacional de Proteção de Dados (CNPD);  
 Administration boards (AB) of all the sites involved.  
According to INFARMED statistics, the number of CTAs in Portugal has also faced a 
decreasing period. Furthermore, there is a clear reduction in the number of early stage studies, being 
the majority phase III trials (figure 3) (17). 
 
Figure 3 – Number of clinical trials submitted to INFARMED between 2007 and 2013, by trial phase. Adapted from: 
INFARMED’s Website(17). 
 
 
 
When analysing the principal hurdles for conducting clinical investigation in Portugal it is 
important to mention the difficulty in implementing the trial at the site level (start-up phase). In this 
context, two factors are worth mentioning: 
 Although CEIC is the legal organism for the ethical evaluation of clinical trials, the reality 
is that several national sites do not approve a trial without a favourable opinion of their local 
ethics committee – Comissão de Ética para a Saúde (CES). This unnecessary “double” 
ethical approval might significantly delay the overall approval process. 
 Prior to the initiation of the clinical trial, the sponsor and the trial site must enter into a 
financial agreement. The negotiation process is generally time consuming, mainly due to the 
absence of a financial agreement standardised template.  
2007 2008 2009 2010 2011 2012 2013*
Phase I 7 3 6 2 6 3 0
Phase II 30 31 27 17 19 25 4
Phase III 74 100 73 79 58 82 23
Phase IV 21 12 9 9 5 8 6
Total 132 146 115 107 88 118 33
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*The 2013 data corresponds only to the 1st trimester. 
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2.2. MEDICAL DEVICE’S R&D MODEL 
According to EUCOMED, the European MD industry as estimated market site of € 100 billion 
and employs more than 575,000 persons (18). Compared with medicines, the MD definition encloses 
a completely different range of products, from a simple pair of medical gloves to complex magnetic 
resonance devices (5). Taking this into account, the process of device development can also follow 
different paths.   
Nowadays the majority of new and innovative devices have origin in small start-up companies 
(19) and  in contrast with what happens for new drugs, the process of developing a MD doesn’t start 
with a scientific discovery per se (5), instead the idea normally comes from a physician/engineer that 
conceives an idea for an unmet need and then constructs a prototype (figure 4) (19).  
Figure 4 – The MD development pathway. Available from: Rare diseases and orphan drugs: accelerating research 
and development, 2011(5). 
    
 
Generally it is possible to test several devices’ properties in an engineering setting before 
moving to non-clinical testing. The non-clinical phase normally has 2-3 years of duration and its 
funding usually comes from venture capital firms (19). Although the overall process is generally 
represented as a series of sequential phases, in reality it is a continuum process with several feedback 
loops that trigger constant device’s adjustments and new tests (20).  In terms of clinical evaluation, 
usually innovative MDs are subjected to a first-in-man/pilot study i.e. a preliminary study to assess 
if a larger study is practical and to refine its study protocol. This “feasibility” study is then followed 
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by a pivotal study, which will involve more participants, and will generate the data needed to support 
the MD safety and effectiveness evaluation for its intended use. 
 However, the clinical evaluation process is dependent on the risk category of the device and 
it may not involve the execution of clinical studies (as it is explained below). 
In contrast to medicines that generally stay in market for several decades, MD can be changed 
while in development and in average only takes 18-24 month to get a new and improved version of 
an already marketed device (4).   
 
2.2.1. CLINICAL STUDIES – REGULATORY FRAMEWORK 
While the European legal framework of medicines has been in place since middle 1960s 
(pushed by the thalidomide tragedy) a systematic regulation for MDs only appeared in the 90s. Before 
that  each country had their own requirements: some countries had no regulatory requirements at all, 
others had published regulations only for certain type of devices (taking in account their perceived 
risk) while others classified/treated some MD as if they were pharmaceuticals products (21-23).  
 To facilitate trade within the EU single internal market, the EU has published a set of 
directives, known as the New Approach Directives and that cover a range of products, including MD. 
These measures intended to provide control on product design and above all, to seek for 
harmonisation regarding product safety requirements across Europe.  
The main MD directives include: directive 90/385/EEC concerning active implantable medical 
devices (AIMD), directive 93/42/EEC, concerning MD in general and directive 98/79/EC concerning 
in vitro diagnostic devices. The Directives 90/385/EEC and 93/42/EC were amended by the Directive 
2007/47/EC of the European Parliament and the Council of 5 September 2007 (21).  
Besides the directives, there are other no legally binding documents, related with the 
conduction of clinical investigation that are worth mention:  
 MEDDEV 2.7/4 – Guidelines on Clinical investigations: a guide for manufacturers and 
notified bodies: this document addresses considerations for the need to conduct a clinical 
study and their design (24);   
 MEDDEV 2.7/3 – Clinical investigations: serious adverse event reporting: This document 
provides clarification for the reporting criteria for adverse events (24); 
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 International standard EN ISO1 14155:2011: provides practical guidance concerning the 
conduction and reporting of clinical investigations. Its consider the GCP equivalent for 
clinical studies (24). 
On September 2012, the European Commission adopted proposals to revise the EU regulatory 
system for MD and that are expected to be adopted in 2014 and come to force in the period from 
2015-2019 (25).  
MD can been divided into four risk classes, according to their level of risk, from class I (low 
risk) to class III (high risk).  The risk class is based on several criteria, such as the intended duration 
of use, degree of invasiveness and the body part affected 
(21)...…………………………………………………………………………. 
Unlike what happens with medicines, the competent authorities are not responsible for 
assessing or authorising the entrance of a MD in the market. Instead, they can only be placed on 
European market if presenting the CE marking - a proof of conformity with the list of “essential 
requirements” defined in the MD directives. Custom-made MD and clinical research MD are 
exceptions, and do not need to bear the CE mark (figure 5) (21). 
 
Figure 5 - The CE-marking process. Available from: CE-marking Association website(26). 
 
 
It is the manufacturer’s responsibility to perform the evaluation of conformity. However, for 
class I sterile devices or with a measuring function, and for class IIa, IIb and III devices it is required 
the intervention of a third party for the assessment of conformity - the Notified Body (27). 
                                                     
1 International Organisation for Standarisation 
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The demonstration of conformity is based on “clinical data”. Moreover, the recent amendment 
to the MD Directives establishes that all MD must have a clinical evaluation report in its technical 
file, regardless of its risk class (26).  
This data can be originated from clinical investigation studies (the “clinical investigation 
route”), from a compilation of the relevant scientific literature (the “literature route”), or even from 
a combination of both (22). In general terms, active implantable, implantable and class III MDs 
require the conduction of a clinical study.  Depending on clinical claims, risk management outcomes 
and on the results of the clinical evaluation, clinical investigations may also be required for non-
implantable MD of classes I, IIa and IIb MDs (28) (table 1). 
 
Table 1 – Clinical evaluation process for MD. Adapted from: LNE/G-MED North America website(24). 
 Clinical evaluation 
Compulsory for obtain the CE Mark 
Risk 
level/product 
type 
For MD with 
equivalent products on 
the market 
For class I, IIa, IIb non 
implantable MD 
Common used 
products 
For MD with equivalent on 
the market that required 
further investigation. For 
class I, IIa, IIb and III 
New, innovative MD with no 
market equivalents. 
Compulsory for class III MD 
and implantable devices. Can 
be considered for lower risk 
classes. 
How to meet 
the 
requirements 
Basic literature review Advanced literature review 
to assess risk/benefit ratio 
Robust clinical investigation to 
demonstrate a favourable 
risk/benefit ratio 
 
Expertise 
required to 
meet goal 
 
Medical writer 
 
 
Medical writer, medical 
adviser and statisticians 
 
Medical writer, medical 
adviser, project manager, 
patients and heath care 
professionals 
 
2.2.2. CLINICAL STUDIES IN PORTUGAL 
The MD directives were transposed to the national law by Decree-Law nr. 145/2009, June 
17th. Decree-Law n. º 46/2004, of 19 August, relating to clinical trials, is also applied.  
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Contrarily to what happens with clinical trials, the pathway to obtain the approval for the 
conduction of a clinical study does not involve CEIC. Instead it begins with getting the ethical and 
institutional approval from each site involved; in parallel it is still necessary to obtain approval from 
CNPD. It is only after obtaining all these approvals that it is necessary to notify INFARMED about 
the intention of conducting a clinical study (29). 
There is no available data about the number of clinical studies conducted in Portugal. 
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3. ACTIVITIES DEVELOPED 
The main activity developed during my internship happed in the context of Blueclinical R&D 
business unit, and correspond to the management of a clinical study. Fortunately, I also had the 
opportunity to develop other activities in the other two company business units and attend to several 
meetings and training sessions that were very enriching and allowed me to develop and deepen some 
knowledge already acquired during the master’s degree. 
Unless otherwise specified, the activities were assigned to me by e-mail and were performed 
home-based. 
 
3.1.  GENERIC TRAINING 
This section describes the different training sessions, visits and reunions attended during my 
training period, as well as the theoretical knowledge acquired during the same. 
 
3.1.1. BLUECLINICAL’S QUALITY MANAGEMENT SYSTEM 
In a training activity that took place in the phase I unit on 8th May 2013, I attend to a 
presentation about the company’s QMS and some basic concepts regarding quality management. 
A QMS encompasses four basis components: quality control (QC), quality assurance (QA), 
education/training and a set of clearly documented writing procedures.  
QA is defined by the ICH E6-Guideline on GCP as all those planned and systematic actions 
that are established to ensure that the trial is performed and the data is generated, documented 
(recorded), and reported in compliance with GCP and the applicable requirements (30).  QC 
comprises the operational techniques and activities undertaken within the QMS to verify that the 
requirements for quality have been fulfilled (31). In other words, QC is embedded into the operations, 
being integrated on the daily activities. QA, in contrast, is the responsibility of a department, 
independent of the operational units, sometimes may be even subcontracted to a third party, and it is 
focused on providing confidence that the quality requirements are being fulfilled (31). 
The  hierarchy and types of quality documents relevant to quality systems depends upon the 
company business objectives and model (31). Blueclinical’s quality documents hierarchy is 
organised in three levels. The higher level is composed through the quality manual and the code of 
conduct. The medium level and low level are constituted by standard operations procedures (SOP) 
and supporting documents, respectively.  
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The quality manual describes the company QMS and the code of conduct consists in a set of 
principles issued by Blueclinical aiming to help their collaborators to conduct business with honesty 
and integrity. During the training activity mentioned above, all the Blueclinical’s collaborators had 
the opportunity to give their input in terms of what they consider important to be present in the code 
of conduct. 
 SOPs are  defined as detailed, written instructions to achieve uniformity of the performance 
of a specific function (30). In other words, a SOP specifies in writing who does what, when and how 
to perform a determined activity or process. The purpose is to ensure that every task is done in a 
consistently way by all the company collaborators involved (31).  Ideally, they should be written by 
the people that will use them and the language must be clear and unambiguous. Its distribution must 
be controlled; this means that they must be reviewed before approval and release, any change must 
be re-evaluated and their distribution must be documented and controlled. When a SOP becomes 
obsolete, there should be procedures in place to prevent their use (31).  
The supporting documents are documents used to complete/record a specific task, which can 
be described in a SOP or not.  
Blueclinical’s SOP for SOPs describes how the other SOPs/supporting documents must be 
written, their structure and format, the person responsible for the approval and the periods for 
revision. It has also a template for the construction of a new SOP as an appendix (32).  
SOPs along with other relevant quality documents ensures the effectiveness and efficiency of 
quality systems (31).  
Having all the above in mind, SOPs are excellent training tools when starting a new job 
position in a clinical research company. 
 
3.1.2. BLUECLINICAL PHASE I 
During my training I had the opportunity to visit the phase I unit several times while it was in 
construction and to observe to some of the processes that were necessary to adapt and equip the space 
conveniently. Moreover, on a training activity that took place on 8th May, I had the opportunity to 
visit the unit already finished and practically equipped and to meet the investigational team. Along 
the way, I tried to understand and discover more about phase I trials and available guidelines for 
phase I units. 
According to the Association of the British Pharmaceutical Industry guidelines, a phase I unit 
must have the enough space to conduct the planned trials (7). Also, and to allow an appropriate risk 
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management, the units must be  located close to/ in a hospital with acute/emergency settings or an 
intensive care unit (7). An alternative is to have the required equipment to ensure cover for medical 
emergencies by itself.  
In terms of facilities, Blueclinical’s phase I unit has: 
 11 bedrooms (4 double, with private bathroom, and 7 triple).  The rooms are equipped with beds 
on wheels, adjustable for height and tilt. The furniture’s distribution was planned to allow 
moving medical equipment in the rooms.  As subjects must be under supervision of the staff 
personnel while inside the room, the rooms have windows directed to the corridor; 
 A separated office for medical examinations, in order to ensure the required privacy; 
 A pharmacy. This room has restricted access only for authorised staff and has the adequate 
conditions for the drug supplies (e.g. temperature and humidity control/recording, and protection 
from direct light); 
 Laboratory, with appropriate equipment for processing and storage of the biological samples; 
 Living and dining room; 
 Two work offices; 
 One room for sample collection; 
 A room with lockers for the volunteers to save their belongings;  
 A room for the computer server; 
 Staff’s locker room; 
 Male and female WC’s and showers; 
 The unit has controlled access, and there are synchronised clocks distributed in the corridor to 
guarantee that the team elements are coordinated.  
The unit functioning is also assured by support services that are provided by Hospital da 
Prelada, namely security, alimentation, cleaning and laundry, and emergency services. 
Phase I trials include a range of studies, namely: 
 First-in-man trials - consist in the administration of single ascending dose in order to get insight 
in terms of the drug tolerability, safety, PK and pharmacodinamic (if possible). 
 Subsequent trials – that include: 
o Multiple ascending doses;  
o Trials to evaluate the potential influence of food,  concomitant medication, gender, age 
and genetic differences on the activity of the drug candidate; 
o Trials to assess the dose/concentration-activity relationship; 
o Evaluate the PK of radiolabelled IMPs; 
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o Bioavailability (BA) or bioequivalence (BE) trials; 
o Assess the effect of the IMP on the QT interval (7).  
Generally, these trials are conducted in healthy volunteers, from both genders and older than 
18 years. Healthy subjects are generally easier to find and not taking concomitant medicines increases 
the probability of an uniform response (7). In other words, it helps separating the effects caused due 
to the study intervention from those caused by any disease/medication that patients may have taken 
or may be taking. Trials for IMPs that present serious risks, such as potential oncologic drugs are 
conducted in patients (33). The total number of subjects included varies with the study drug and 
study type, but it generally ranges between 20 and 80 participants (7).   
Regarding the subject recruitment methods, Blueclinical’s website has a specific tab where the 
potential volunteers can complete an online form. Since the website collects subjects data and may 
be considered a mean of advertisement its content was evaluated and approved by CNPD and CEIC. 
Other methods used worldwide include advertisements in newspapers/magazines or on notice boards, 
radio, commercials on TV/websites or by recommendation from others.  Regardless of the 
recruitment method used, the subjects must be capable of voluntarily providing valid consent and 
should be properly informed and clarified for any questions they have (7). 
The health status of the volunteers is judged during the screening activities. Blueclinical’s staff 
contacts by telephone the potential candidates i.e. those registered in the website’s database, and 
provide them with trial-related information (e.g. study design and duration, IMP’s characteristics, 
possible adverse events, etc.). If the subject is still interested a medical evaluation must be conducted 
at the phase I unit facilities. This visit will include signing the informed consent form (ICF) and then 
recording the patient medical history, performing a physical exam and conducting a series of blood 
and urine analysis, like testing for drugs of abuse, HIV, hepatitis B and C and also pregnancy test in 
women with child-bearing potential. Depending on the trial specificities, other exams may be needed. 
After reviewing all the results from the screening visit procedures the subject is informed if he 
is eligible to participate or not. During this process he can decide at any time to decline participation. 
Lab analysis is required for safety reasons and for PK (bioanalysis). In both cases, sample 
collection and preparation is performed at the phase I unit. Safety analysis is performed at Hospital 
da Prelada. These analysis usually are conducted during screening, but also at admission, medical 
discharge and during the follow up period. Bioanalysis performed by Anapharm Europe lab, at 
Barcelona, Spain.  
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As these trials usually have non-therapeutic objectives, the study participants are normally 
compensated for their participation. The value for compensation must be previously approved by 
CEIC and must never be proportional to apparent risk (34). 
In terms of regulatory/ethical approval, phase I trials follow the same principles as all other 
studies, and, in Portugal, require the approval from the relevant ethics committee (CEIC) regulatory 
agency (INFARMED) and CNPD.  
This journey was very enriching and gave me a valuable insight about the logistics and the 
organisation of a phase I unit. 
 
3.1.3. BLUECLINICAL SMO 
During this 9 month period I attended to two training sessions regarding Blueclinical’s SMO 
mission and strategy. I also had the opportunity to be present on several meetings where the SMO 
service was presented to several medical investigators. Those meetings happened with three main 
purposes: to present Blueclinical,  to assess the investigators interest in having a CSC on the 
investigational team and last, to collect information about their main interest in terms of therapeutic 
areas for conducting new clinical trials.  
The referred training sessions along with the meetings attended allowed me to develop a 
deeper knowledge about the nature of a SMO service, the role of a CSC and the dynamics of a clinical 
site, which I present below. 
A SMO is an organisation specialised in providing clinical trial related services to clinical sites 
(1). As referred, the purpose of Blueclinical SMO is to improve the capacity of the Portuguese sites 
to carry over clinical research activities. This objective is accomplished by placing fully dedicated 
and highly qualified clinical CSC in the institutions, who will be integrated onto investigational teams 
and take on meaningful assignments in the conduction of the clinical research.   
Until the middle 1970s CSC positions were rare, but since then they have been increasing in 
number. Currently a research team includes the PI, sub investigators, nurses, pharmaceutical services 
and technicians. In some sites it also is the figure of the CSC. While the responsibilities of the 
investigators, sponsors and clinical research associates (CRA) are well established in the Portuguese 
law for clinical trials and in the GCP guideline, the same does not happen for CSC (35). 
The purpose of Blueclinical SMO is for their CSCs to develop a deep knowledge about the 
study protocol, including the inclusion and exclusion criteria, study procedures and timelines, 
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assuming responsibility for coordinating the daily clinical trial activities, since the beginning until 
the study conclusion.  
The general responsibilities of a CSC include:  
Pre-study activities: Before the study start, the CSC assists the PI in the completion of the 
feasibility questionnaires2 that are received from different CROs and sponsors. Following that, and 
if the sponsor/CRO decides to perform a pre-site selection visit, the CSC is also responsible for 
accompanying the CRAs and answer to all of their questions. If the site is selected, CSC will became 
the point of contact with the sponsor and provide all the necessary documents (e.g. templates 
available, study team CVs, etc.) for the study submission to the national/local ethics committee. 
Study activities: CSC often collaborate with the PI in communicating the study requirements 
to the other team members (internal training).  They also participate in the informed consent process, 
helping the investigators communicating the study information to patients and by assuring that the 
correct version of the ICF is being used, and it is timely and appropriately signed and dated. 
 During the study conduction, CSC are responsible for preparing and scheduling the study 
visits. During these visits, they must assure that all the medical data/ biological samples are collected 
according with the protocol and they also can take responsibility for administering the study 
questionnaires to patients, when required. In the case of adverse events they must also collect and 
register all the relevant information. After completion of the entire visit procedures CSC have to 
enter data in the case report forms (CRF), perform drug accountability and calculate treatment 
compliance. Between visits, they must assure adequate inventory of study supplies and maintain the 
study files organised according to sponsor’s requirements.  
During the study conduction, routine monitoring and auditing visits should be expected. CSC 
must prepare the study files for these situations and then collaborate with the PI to respond to any 
audit/monitoring findings by implementing the necessary corrective measures. 
Closeout activities: When a study ends, CSC must assist the PI in the submission of all the 
necessary closeout documentation. They will also collaborate with the trial’s CRA to arrange a secure 
place for the study documents, always in compliance with the site procedures and the contracted 
length of time. 
Having this description in mind, it is clear that hiring professionals specifically dedicated to 
clinical research has an undeniable influence in improving the efficiency and productivity of the 
research centers.  However, along the way I realised that many of the investigators to whom 
                                                     
2 Questionnaire intended to assess the suitability of a certain site to conduct a study, i.e. investigator 
qualification and experience, existence of experience clinical staff and adequate infrastructures, etc.  
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Blueclinical SMO service was presented were not familiar with the role of the CSC, while others 
associated this role to purely administrative tasks, which is a much diminished vision about the role 
of a CSC.  
Besides this, Blueclinical SMO also intends to organise and maintain the institution’s quality 
system for clinical research, to train and certify the staff in GCPs and to actively seek for new 
sponsors and new studies to implement in the institution. 
 
3.2. MAIN ACTIVITY – MANAGEMENT OF A CLINICAL STUDY 
As an associate project manager, I formally belong to the Blueclinical R&D business unit.  
As already stated in the “host company overview” section, one of the services provided by 
Blueclinical R&D consists in obtaining regulatory approval for clinical trials/studies.  During my 
training period, Blueclinical was contracted by an international sponsor to implement a clinical study 
with an AIMD (i.e. medical device whose function depends on an electric source of energy that is 
not generated by the human body/gravity and that is intend to be totally or partially introduced into 
the human body and remain after the procedure (21) ) in five national sites. The study was already 
on going in other countries and Portugal was included as a rescue country to achieve the recruitment 
targets. 
The process of obtaining all the regulatory authorisations and approvals needed for initiating 
a clinical study is commonly classified as “pre-study activities”. 
When this task was assigned to me, the first step was to carefully read the master service 
agreement (MSA), the sponsor’s procedures and the study documents. I also had to get familiar with 
the applicable legislation. 
The majority of the documentation can be submitted in English. However, the ICF, 
information for patients and the clinical investigational plan (CIP) synopsis must be written in 
Portuguese.   
My first activity was to perform the translation of the CIP synopsis to Portuguese and check 
the accuracy of the ICF translation. The translation turned out to be quite challenging, due to the 
several technical/medical terms used, which required some research.  
In Portugal, and as already referred, a clinical study with an AIMD requires the approval of 
the following entities: local ethics committee (CES) of each site involved. AB of each site involved, 
CNPD and INFARMED. 
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3.2.1. OBTAIN ETHICAL AND INSTITUTIONAL APPROVAL 
The minimum information requisites when submitting a clinical study for evaluation by the 
local ethics committee is established in the INFARMED deliberation no. 514/2010 (36). However 
each ethics committee has its particularities and in spite the basis for their work is the same 
deliberation they have different requirements amongst themselves. 
Having this in mind, the first step was to contact with the research sites to obtain information 
about any specific documentation required and to understand the evaluation pathway within each 
site. 
The documentation required included, in general terms, the following: 
 CIP and a CIP synopsis in Portuguese; 
 Cover letter; 
 Investigator brochure; 
 CRF; 
 ICF and information for patients; 
 Authorisation from the head of the department; 
 Authorisation request to the ethics committee president; 
 Study team’s Curriculum Vitae (CV); 
 Ethics committee’s specific questionnaire/form;  
 Authorisation request to the AB president; 
 CNPD authorisation; 
 Insurance policy; 
 Clinical site agreement (CSA)/financial protocol. 
For the purpose of tracking the retrieval of mandatory documentation, I created a 
template/checklist, which I updated for each site whenever there was new information available. This 
tool turned out to be extremely helpful to organise my work more efficiently.  Whenever a site did 
not have a specific template available for the authorisations request, I had to create one to propose 
them, which ended up being quite a frequent approach as most sites do not have standard operating 
procedures or forms. 
The topics covered by the ethics committee questionnaire were similar for all the sites and 
included: 
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 General information about the study: study objectives, study design, other national sites 
involved. 
 Study population: who is the target study population? How will the informed consent  be 
obtained? 
 Information about the data to be collected, the methods for collection and how the data’s 
confidentiality/patient privacy is ensured. 
 Risk-benefit: what are the expected benefits and risks/inconveniences for the study participants?  
 Planned payments to patients:   will the patients be reimbursed by travel costs? In case of damage 
caused, is any compensation planned?  
The CSA is a legally binding document used between the sponsor and the clinical site that 
establishes the terms and conditions associated with the conduction of a clinical study (e.g. 
insurance/liabilities, intellectual property/publications, payment, data protection, safety reporting, 
etc.) (37). The execution of the CSA is often viewed as one of the main reasons for delays in a study 
start up.  Although the sponsor had provided us with an already prepared CSA (sponsor’s template), 
some sites had their own financial contract templates that had to be followed. As a strategy, and to 
facilitate both the site and the sponsor’s agreement, site templates were included as an “appendix” to 
the sponsor’s CSA, from now on referred to as financial protocol. 
The completion of those templates involved the following general steps: 
 Identify all the medical procedures/exams required as per the CIP. 
 Calculate the indirect costs (e.g. medical procedures/exams costs, patient expenses 
reimbursement). The calculation of the amount due for medical procedures/exams required 
consulting Portaria no. 839-A/2009, that determines the prices to be charged according to the 
national health service price tables, and Ordinance no. 306-A/2011 regarding patient fees. 
 Calculate the direct costs (i.e. payments to the investigational team). This activity involved close 
contacts with each site’s PI to get the amount due to the whole investigational team divided by 
the different team elements. 
Prior to the submission per se, all sites performed a pre-evaluation of the financial protocols. 
Thus I had to prepare a draft version of the CSA/financial contract, which was submitted for site’s 
revision and approval.  The entity responsible for performing this pre-evaluation differed from site 
to site (e.g. pharmaceutical services, the hospital financial department or the investigational center).  
In order to be more effective in my work, I have identified a point of contact at each site to 
whom I resorted to follow up the process or to request for clarifications. Due to the particular 
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characteristics of the study design – the randomisation of the study patient occurs during his 
hospitalisation – the site often raised questions that had to be promptly addressed by me.  
After collecting all the information needed and preparing the submission dossier, I arranged a 
meeting with the PI/CSC for collecting all the missing signatures and for hand delivering the dossier 
to the ethics committee. 
During this process I was challenged to elaborate a writing procedure about the submission 
process in each site. The purpose was to create a document that would facilitate the work of other 
Blueclinical’s collaborators when dealing with the same sites in the context of a clinical study 
submission. At the same time, this task turned out to be a good systematisation exercise. 
 
3.2.2. CNPD APPROVAL 
According with the Law 67/98 from October 26th  it is mandatory to submit and get approval 
from CNPD for all the clinical studies/trials that involve the management of personal data and/or 
sensitive personal data(38).  
The submission is performed electronically via an online form – the general notification form.  
The information requested by CNPD includes: 
 Type of data collected and method for collection i.e. direct or indirect collection; 
 Period for data storage; 
 Security measures implemented for data protection; 
 Existence of interconnection of data (e.g. when there is a possibility of correlating data in a file 
with data from other files kept by the same or others parties) (38); 
 Existence of transmission of data to outside the Europe/European Economic Area; 
 How the right of access is ensured. 
Due to the specifics of the information requested by CNPD, the completion of this form 
required a close contact with the sponsor. 
 After the electronic submission, the applicant receives instructions on how to pay the fee and 
an e-mail is sent to CNPD to conclude the submission process. The e-mail I sent included the 
following attachments: copies of the application form, the ICF, the CRF and the CIP synopsis. 
Sending the CIP is a common strategy as it provides additional detail that can avoid the number of 
CNPD additional questions, thus avoiding delays in the approval process. 
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CNPD has no legislated deadline for issuing its authorisation. However, on average, it takes 2 
to 3 months. 
The CNPD submission was done in parallel with the submissions to the study sites as a strategy 
to save time. For this, I had to include in every submission dossier the following: a statement of 
commitment (signed by the sponsor) to not initiate the study before obtaining all necessary approvals, 
a copy of the submission form and the fee payment proof. When the authorisation was issued, I 
entered in contact again with the local ethics committee to provide a copy of the CNPD approval 
letter to complete the submission dossier. 
 
3.2.3. INFARMED SUBMISSION 
While the process was under evaluation by the ethics committees I started preparing the 
INFARMED submission. According to the national legislation, for class III, implantable, and 
invasive for long term use class IIa or IIb MDs, the manufacturer can initiate the clinical study 60 
days after the notification to the competent authority. For other devices the clinical study can initiate 
immediately after  INFARMED notification (29). 
The INFARMED notification involves submitting the same documentation included in the 
submission dossiers to the sites plus the ethical approval letters/AB authorisation letters already 
issued, the approved and signed financial protocols and the device’s labels. Additionally, it is 
necessary to have the “Statement of Clinical Investigation with AIMD” and the “Form for AIMD in 
Clinical Investigation”, both available at the INFARMED’s website, completed and signed by the 
sponsor (39). 
Regarding the device’s label, the national legislation has clearly established requirements 
(numbers 17, 18, 19 of Annex X) (40). In this context, I had to analyse the device’s documentation, 
to check for compliance with the national requirements and to perform the necessary adjustments. 
This analysis and sharing it with INFARMED allowed the sponsor to get a waiver on the translation 
of the full label into Portuguese, i.e. a simplified label has been authorised thus speeding up the 
submission process. 
In contrast with what happens with clinical trials for which there are clear indications about 
the format for the application to INFARMED, there is no information available on the required 
submission structure for clinical studies. For this reason I had to create a structure, which was based 
on the “instructions for applicants” for clinical trials that are available at the INFARMED website. 
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The submission to INFARMED was made in a mixed format (paper and CD–ROM), by 
regular mail.  
 
3.2.4. STUDY PRESENTATION TO OTHER POTENTIAL INVESTIGATORS 
In the middle of the regulatory submission to the selected sites I had the opportunity to perform 
a study presentation to Investigators from a new site. The purpose was to assess their interest in 
participating.  
 
During this 9-month period, four out of five of the sites selected approved the study, as well 
as CNPD and INFARMED.  
In the end I had to organise all the submitted study documentation along with all the relevant 
correspondence per site and provided to the sponsor. Also, all the approval/opinion letters and the 
correspondence selected had to be translated to English by me. 
 
3.3. OTHER ACTIVITIES 
In parallel with the activities described in the previous section, I engaged a series of other 
activities described below. 
 
3.3.1. WRITING PROCEDURES 
 Taking my curricular training in a new-born company gave me the opportunity to draft several 
SOPs and the respective forms, namely: 
 Site initiation visit  
o Template for a site initiation visit report 
o Patient enrolment and identification log 
o Delegation of tasks to study Staff 
o IMP/ MD release 
o Site visit log 
 Routine monitoring visits  
o Template for a monitoring visit report 
o Screening log 
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o Enrolment log 
o Contact report form 
o Close-site visits  
o Template for close-site visit report 
o Record retention form 
 Trial Master File (TMF) (referred on page 30) 
o Archive index/log 
o Documents track 
 Clinical study submissions (referred on page 25) 
The sources of information used include, obviously the Blueclinical’s SOP on SOPs, but also 
the applicable regulations and guidelines and any available technical informational, like published 
handbooks and manuals. 
In the middle of the process the company decided to readapt their SOPs, opting by a new, 
simpler and more intuitive SOP structure.  I had to adapt the following SOPs according to a new SOP 
template: 
 ICF 
o ICF template 
o ICF QC checklist 
 Compensation to healthy volunteers 
o Request for compensation for healthy volunteers 
o Payments control 
 Phase I clean-ups 
 Phase I uniforms 
 Selection and training of medical investigators 
 
3.3.2. PREPARATION OF A NATIONAL SITE IN THE CONTEXT OF BLUECLINICAL 
SMO 
During the last year, Blueclinical SMO has established a protocol with some national hospitals 
and during my training period I had the opportunity to spend two weeks in one. I went together with 
a Blueclinical’s collaborator that was doing her professional training as an associate CSC.  
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The site where I had the opportunity to work had never had a CSC. The CSC activities 
described in the “generic training” section have been done by the study nurses, the investigators or 
the investigational center coordinator.  
My stay on that hospital happened with the purpose to characterise the hospital performance 
in terms of clinical research during the past five years. For that, I have been involved with: 
  Revision of the TMF – The TMF consists in the study’s essential documents, which allows the 
evaluation of both the trial conduction and the quality of the data produced (30). The revision of 
the study documents included checking for discrepancies or missing documents.  
 Clinical trials/observational studies database construction - The information collected 
included: type and number of studies (e.g. clinical trial vs. observational study) and their status 
(e.g. ongoing vs. concluded), therapeutic area concerned, investigators involved and their 
contacts, sponsor identification, recruitment rates (number of proposed subjects vs. recruited 
subjects), payment per patient and responsible CRA and their contact. 
 CV collection – the collection of a signed, dated and updated version of all the investigational 
team members CVs is often a limiting step when trying to submit a new clinical trial. Having 
said that, I collected all the CVs already available and prepared a new draft version according to 
a new standardised format. 
 Elaboration of a financial report – Using the data collected, I wrote a draft version for a 
financial report, which included payments performed for every industry-sponsored study, per 
year, distinguishing between clinical trials and observational studies. I also compared it with the 
value that would have been received if the investigator was able to accomplish the recruitment 
target. 
 Writing procedures - it is also Blueclinical’s responsibility to outline the quality manual for 
clinical investigation and also all the relevant procedures. In this context, I wrote a draft version 
for a procedure concerning the organisation and maintenance of the TMF, both and English and 
Portuguese (already listed above). 
These activities allowed me to contact with different study documents from different sponsors 
as well as to contact with the day-to-day activities of a national investigational center. Additionally, 
it allowed me to work with new colleagues. For these reasons, I consider it a big learning opportunity.  
 
3.3.3. BIOEQUIVALENCE TRIALS - LITERATURE RESEARCH 
A BE study works as a proof of the clinical effectiveness and safety of a generic drug since it 
is scientifically accepted that if the blood concentrations of the active ingredient of two drugs are the 
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same, their concentrations at the site of action are the same and their clinical behaviour will 
consequently be the same (41). Two drug products are considered bioequivalent if there is no 
clinically significant difference in their BA. BA is the measurement of the rate and extent to which 
the active ingredient or active moiety is absorbed from a drug product and becomes available at the 
site of action(42). It is assessed through three PK parameters: area under the curve (AUC), peak 
concentration (Cmax) and time to reach Cmax (Tmax) (41). 
As any other trial, a BE trial needs to be described in a scientific and ethically sound study 
protocol. When designing the study it is essential to spend some time analysing the applicable 
regulatory guidance and collecting detailed information about the brand product(42).  In this context, 
I was asked to conduct a literature search to compile relevant PK information for a set of marketed 
drugs, including:  
 Cmax and tmax - gives information to correctly distribute the sampling collection points.  
 Drug’s half-life (t1/2) - provides information about how long it is necessary to collect samples. 
 Cmax and AUC’s intra-subject and intra-individual variability.- gives information regarding 
the number of subjects required. The intra-subject refers to the variability that it is observed 
when repeating the same experiment on the same subject and under the same conditions; the 
inter-subject variability is the variability observed in different subjects under the same 
experimental conditions (43).  
The sources of information consulted included the approved summary or the product 
characteristics, and related scientific papers available.  
This activity allowed me to review concepts already learned during the master’s degree. 
 
3.3.4. QREN APPLICATION 
During my training period, I had the opportunity to write some texts for a QREN’s application. 
QREN stands for Quadro de Referência Estratégico Nacional and it constitutes the framework for 
the implementation of the community’s policy on economic and social cohesion in Portugal in the 
period of 2007 – 2013. In simple words, it is a reference document that presents the country’s strategy 
and the themes chosen for the structural funds (Fundo Social Europeu and Fundo Europeu Agrícola 
de Desenvolvimento Rural) and the Cohesion Fund’s intervention) (44).  
Bearing in mind the different characteristics of the different companies that constitute our 
national economic environment, three incentive systems were established: the System of Incentives 
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for Research and Technological Development, the System of Incentives for Innovation, and the 
Incentive System for Qualification and Internationalisation of small and medium enterprises (44). 
The presentation of applications to the different incentive systems happens by contests that are 
open through the publication of the Notice of Opening, in Portuguese “os Avisos de Abertura”. These 
notices establishes  the contests’ objectives and criteria, deadlines for application’s submission, 
methodology for the determination of the project’s merit/score, budget for incentives granted and 
what expenses are eligible/illegible (44). 
The projects received are then sorted in descending order according to the project’s merit and 
until the budget limit established in the Notice of Opening is depleted. In case of equivalence the 
criterion for distinction is the date of application.  
When I engaged this task I attended to a meeting with the person responsible for that kind of 
projects where I had the opportunity to participate in sorting the most appropriate contest for a 
company having Blueclinical’s characteristics. 
The application form is available online. The information required included, among others:  
 Company’s history/evolution; 
 Company’s general information (e.g. address, zip code, URL, share capital, date of start of 
activities, etc.); 
 Company’s staff and respective level of qualifications; 
 Justification of the project’s inclusion in the selected contest; 
 Description of the services provided; 
 Auto-analysis of the project’s merit and justification according to the criteria established in the 
Opening Notice. 
 
3.3.5. DATABASE CONSTRUCTION 
In parallel with the activities already described, I engaged other smaller tasks that although 
may have taken a smaller part of my time, were also interesting challenges:  
 Microsoft Office Excel database construction concerning marketed in-vitro MD and their 
functions. 
 Information collection concerning national hospital centers, the population served and the 
respective clinical directors and their CVs, when available. The purpose of this information was 
related with the Blueclinical SMO business unit, since Blueclinical is searching for new hospitals 
to established new partnerships.  
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3.3.6. TRANSLATION ACTIVITIES 
Besides the study documentation/correspondence already referred, I also performed the 
translation of two different models of confidentiality agreements. 
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4. DISCUSSION 
4.1. DIFFICULTIES FELT AND STRATEGIES USED 
First of all, I have to refer that having the opportunity to work with a clinical study constituted 
a very interesting challenge, mainly for two reasons: my academic background was always more 
directed to clinical trials, and while there is already established procedures and a good level of 
knowledge of the procedures in place with clinical trials, the same does not happen with clinical 
studies.  
In fact, when I contacted the sites, only one had a prepared list for clinical studies; the other 
sites provided us with information available for clinical trials or observational studies instead. In 
order to overcome this issue, I had to prepare and add to the submission dossier a document that 
briefly explained the legal framework applicable to clinical research with MD. 
Working with five sites at the same time, obliged me to deal with lots of different documents, 
deadlines and persons. Also, I had to create my own “project management tools”: 
 Contact report form – it consisted in a simple Microsoft Office Word document where I 
registered the name of the person I have contacted, the contact date and a summary of the 
conversation taken/follow-up actions agreed. This “tool” was especially useful at the beginning, 
when I wasn’t completely familiar with the procedures in place at each site. 
  Issue management log (table 2) - The purpose was to create a document where I could register 
every problem that occurred. I ended up registering also the different study tasks/steps for each 
site and the respective status. This allowed me to have the situation under control, ensuring that 
nothing was forgotten. Moreover, the document turned out to be very useful when I had to 
provide the sponsor with the project status reports.  
 
Table 2 – Issue management log layout 
 
 Purchase order log (table 3) – it consisted of an Microsoft Office Excel spread sheet that 
allowed me to associate the sponsor’s work orders and the respective purchase orders’ number 
with a description of the different services performed by Blueclinical, their status and the date of 
conclusion.  
 
Site Description Open date Close Date Status Comments Priority 
Site X Xxxx   Open   
Site Y Xxxx   Closed   
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Table 3 – Purchache order log layout 
 
Work Order 
 
Purchase 
Order 
 
Activity 
 
Value 
 
Payment done: add date 
Payment pending: pending 
 
Invoice 
number 
 
Tasks Status 
#1 XXX  xx € Pending  done 
#2 YYY  xxx€ XXMAY2013  pending 
 
Still related to project management, I also highlight the importance and the challenge that 
communication represents. This even gets more complex in the context of international teams, when 
all the parties use English to communicate and this is not anyone’s native language.  
During this process, I had to be obviously in straight contact with the sponsor and with the 
selected sites, including PIs, CSCs and the services responsible for the financial protocol evaluation.  
The main technique used for communicating with the sponsor was the e-mail. The main 
reasons for communication included: request for additional information/documents (as each 
sponsor’s study team member had a clearly and defined role, I had to enter in contact with different 
persons, from different departments), agreed weekly study status updates or even invoicing matters. 
There were periods when this contact happened on a daily basis, because the sponsor was constantly 
requiring clarifications about the national requirements. Since project management is an activity very 
much sensitive to timelines, it was also quite demanding to manage sponsor’s expectations at that 
level. 
The main techniques of communication used with the sites were the telephone contacts and 
the e-mail; face-to-face visits have also been performed. In order to get faster responses I monitored 
the approval status, at least, on a weekly basis with each site.  
Since I have been strongly encouraged from the beginning to be autonomous, I also contacted 
INFARMED directly whenever required to obtain clarifications needed across the whole process. 
In the beginning, all my e-mails were pre-evaluated by a superior, however in the middle of 
the process I gained autonomy at this level and started communicating directly with the sponsor and 
the national sites. 
Writing the texts for the QREN’s application was other task that also occupied a considerable 
percentage of my training period. The main difficulty felt in this task was not directly related with 
writing the texts, but instead in understanding the regulatory framework involved, that was full of 
concepts that were unknown to me. Nevertheless, I was very pleased for having had this opportunity 
since it allowed me to deal with a subject that was completely unfamiliar to me.  
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Regarding the SOPs, one of the main difficulties that I felt during this task was to find a balance 
between writing a short SOP, so the reader does not lose interest, but at same time not forgetting any 
important information.  
 
4.2. LEARNING OUTCOMES 
During this 9 month period I have developed a deep understanding of the national legislation 
for the conduction of clinical studies. I learned how to construct and organise submission dossiers 
and I am now also able to notify a clinical investigations with MD to INFARMED and to perform a 
submission to CNPD. I have also developed some knowledge on business documentation (e.g., MSA, 
work and purchase orders and invoices) and I dealt for the first time with financial protocols. 
This experience also made me testify that there is no place for disorganisation and lack of rigor 
in this setting. Documents must be controlled and the submitted versions must be identified and 
recorded. The quality of the documentation submitted makes the difference between a timely 
approval and a lengthy one, caused by unnecessary delays due to successive clarification requests. 
Although I did not had the opportunity to perform any monitoring  activity, I elaborated three  
SOPs regarding the three types of monitoring visits and the respective supporting documents, what 
allowed me to learn more about this subject and to clarify some misconceptions that I had. 
I also gained a very useful insight about the logistics and function of a phase I unit and the 
dynamics of phase I trials, as well as good level of understanding regarding the QREN’s regulatory 
framework and the submission of applications. 
While the main hard skills gained during this process become clear by simply reading this 
report, there are several soft skills that I definitely had the opportunity to develop/improve during 
this experience. 
Developing the majority of the described activities home-based definitely contributed for 
improving autonomy, organisation, time management skills and critical thinking. During this period 
I was confronted with several new situations that I had to overcome by reading and interpreting the 
legislation in place and by seeking for clarifications contacting directly the entities involved. In terms 
of time management, I learned to prioritise my tasks and began planning my days on the day before. 
This way I ensured that nothing was left behind and things were done quick and efficiently. 
The improvement of my writing/communication skills was something that becomes visible to 
me during the process.  My e-mails became clearer, shorter and objective which consequently made 
communication more easy and effective. 
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Looking back, it is very clear to me that my academic journey at University of Aveiro was 
essential for concluding with success the described activities. Since the beginning of my academic 
journey I have been strongly encouraged to be autonomous, to develop a strong critical spirit and to 
work in teams. The development of these skills started during the bachelor degree thanks to the 
teaching methodology used that confronted students with real life situations that had to be solved by 
studying at home. There is no doubt that the teaching method made a huge difference in terms of 
being prepared for facing new situations. 
The Master’s degree also offered me the opportunity to collaborate with the University’s 
Clinical Research Office. This started during my 1st year in the Master and continued in parallel with 
my training period at Blueclinical. It gave me the opportunity to work on the submission of some 
observational studies to several national centers and to CNPD, which was also a good preparation 
for the activities I had to develop during my training period. Although the process of submitting an 
observational study is much simpler than the process of submitting a clinical trial/study, there is no 
doubt that the previously mentioned experience constituted a tremendous advantage. Moreover, I 
integrated these projects always as a project manager, which allowed me to develop other 
competencies as leadership, motivation and communication skills.  
I also cannot fail to reflect about the opportunities and disadvantages of taking an internship 
home based and in a newly created company. Some of the positive points were already mentioned: I 
had the opportunity to help constructing the company’s QMS by drafting several versions of writing 
procedures; I assisted to part of the process behind starting a phase I unit and I was challenged to 
write some texts for a QREN’s application. I had to do this by trying to be autonomous during the 
whole process.  
Unfortunately I cannot help to recognise some “disadvantages”. As Blueclinical was just 
starting their activities, I only had the opportunity to participate in one project in the context of 
Blueclinical R&D business unit. I also did not have the opportunity of experiencing to work in an 
“office environment”, which I believe may be a contributing factor for “professional growth” when 
a student first leaves the academic setting. 
Nevertheless, I truly believe that I took the best of the opportunities I was given and I know 
that if I had the opportunity to repeat all the activities again I would do it in a much more professional 
and effective way.
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5. CONCLUSION 
This report presented the activities developed during my training period at Blueclinical Ltd, 
as well as the skills and learning outcomes achieved. 
During this 9-month period, I had the opportunity to experience the real work environment, as 
well as to test knowledge and improve competences that I had being developing during my academic 
journey.  
The main activity developed involved obtaining all the necessary regulatory approvals to 
initiate a clinical study in five national sites. I am very glad to have had this opportunity, since it 
allowed me to deepen my knowledge about the MD sector. At the same time it was a challenge due 
to the clear lack of knowledge of the procedures in place regarding clinical investigation with MD.  
Taking my curricular training in a company with three distinct and innovative business units 
was also a great advantage. I had the opportunity to learn about the functioning of a phase I unit and 
also to spend some time in a national hospital, dealing with different study documents and contacting 
with new people. 
I overcame my difficulties by studying the procedures in place and searching for solutions and 
new strategies to organise myself and my work. I believe that my academic background provided me 
with a range of soft and hard skills that were essential for an easier adaption to the work environment 
and integration into the working teams.  I am talking about autonomy, problem solving capacity and 
better communication skills but also about valid knowledge with real applicability in the work 
setting.  
Finally, I want to referrer that I am very thankful for having had the opportunity to integrate a 
company like Blueclinical, with clear innovative services on the national clinical investigation field, 
and to watch their growth during the last months. It was an incredible experience and a great place 
for experiencing my first contact with the work environment. 
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